THERAPEUTIC MANAGEMENT OF HODGKIN'S LYMPHOMA
DOI:
https://doi.org/10.56238/arev8n3-097Keywords:
Health, Hematology, Oncology, Hodgkin's Lymphoma, Therapeutic ManagementAbstract
Introduction: Hodgkin's lymphoma is a neoplasm that affects B lymphocytes. With advances in chemotherapy treatments, long-term patient survival has improved. However, a portion still presents with relapsed or refractory disease, and medications can cause adverse effects such as increased toxicity. Objective: To synthesize and analyze the most recent scientific evidence related to the therapeutic management of Hodgkin's lymphoma. Methodology: Narrative literature review, using articles found in the PubMed database from the last five years, written in full. Results: The ABVD regimen is the most common combination. The drugs Adriamycin, Bleomycin, Vinblastine, and Dacarbazine, although contributing to high chances of cure, also have toxic potential. Bleomycin can affect the pulmonary system, while Adriamycin can affect the cardiovascular system. Conclusion: The integration of molecular biomarkers and the improvement of imaging techniques remain essential to refine patient selection for new, high-cost therapies, ensuring that Hodgkin's lymphoma continues to be one of the most curable neoplasms in modern oncology.
Downloads
References
ANSELL, S. M. Hodgkin lymphoma: 2025 update on diagnosis, risk-stratification, and management. American Journal of Hematology, v. 99, p. 2329-2342, 2024.
André MPE, Girinsky T, Federico M, et al. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2017;35(16):1786-1794.
Brusamolino E, Lazzarino M, Orlandi E, et al. Early-stage Hodgkin's disease: long-term results with radiotherapy alone or combined radiotherapy and chemotherapy. Ann Oncol. 1994;5(Suppl 2): 101-106.
BORCHMANN, P. et al. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. The Lancet, v. 404, p. 341-352, 2024.
BURTON, C.; ALLEN, P.; HERRERA, A. F. Paradigm Shifts in Hodgkin Lymphoma Treatment: From Frontline Therapies to Relapsed Disease. American Society of Clinical Oncology Educational Book, v. 44, p. e433502, 2024.
CASTELLINO, S. M. et al. Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma. The New England Journal of Medicine, v. 387, n. 18, p. 1649-1660, 2022.
HERRERA, A. F. et al. Nivolumab-AVD in Advanced Stage Classic Hodgkin Lymphoma. The New England Journal of Medicine, v. 391, n. 15, p. 1379-1389, 2024.
Luminari S, Fossa A, Trotman J, et al. Long-term follow-up of the response-adjusted therapy for advanced Hodgkin lymphoma trial. J Clin Oncol. 2024;42(1):13-18.
Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med. 2012;366(5):399-408
Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med. 2015;372(17):1598-1607.
ZHANG, S. et al. Hodgkin's lymphoma: 2023 update on treatment. Cancer Biology & Medicine, v. 21, n. 2, p. 93-96, 2024.
